Impact of chemotherapy dose intensity on cancer patient outcomes.
about
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patientsCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Predicting neutropenia risk in patients with cancer using electronic data.Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.The effect of chemotherapy-induced anemia on dose reduction and dose delay.Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines.Advances in the treatment of neutropenia.Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project.First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study.Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation.Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort studyA non-natural nucleoside with combined therapeutic and diagnostic activities against leukemiaChemotherapy interruptions in relation to symptom severity in advanced breast cancerTrends in neutropenia-related inpatient events.Evaluating the quality of colorectal cancer care in the state of Florida: results from the Florida Initiative for Quality Cancer CareWeight-based chemotherapy dosing in obese patients with cancer: back to the future.Association of socioeconomic and practical unmet needs with self-reported nonadherence to cancer treatment appointments in low-income Latino and Black cancer patients.Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancerCOST OF FEBRILE NEUTROPENIA TREATMENT IN BOSNIA AND HERZEGOVINA.Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.Psychosocial correlates of appointment keeping in immigrant cancer patients.Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs?Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review.Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Bringing a genomic perspective to the safety of drug treatment in oncology.Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.Impact of genetic polymorphisms determining leukocyte/neutrophil count on chemotherapy toxicity.Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast CancerDNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.
P2860
Q26768126-DACC020C-9BEC-4B1B-9397-8FCF03920787Q26859144-FC343273-E24F-4D70-8425-F6ED09800C13Q31131362-A74691B9-8D1E-4086-A17C-9EE519CB7E00Q33391777-642E3093-2EC3-4DF8-B8BE-7904A3EF3FDFQ33432161-8A92E5F8-56FE-46B4-9C68-E0F53E27ECDAQ33557215-F8336B68-E4A2-4113-822D-25F5F4BA0C73Q34026627-8F4015C0-2AFF-4A92-9558-0D772296C264Q34104990-5AB489F6-40EB-471C-8E4A-FCAE4A010BAEQ34459673-09D9C333-186B-496B-86C2-3B8DD310A82EQ34609244-1D98BC39-4248-4626-A6A5-80681DFFF49CQ35165571-67CA59D9-3D15-4875-B3D6-2F1BB7CEC386Q35165579-B527BEDE-5A4B-47BA-8967-057AFF09301DQ35762244-A6F70F1A-DB93-47B0-8AD2-A1D540B06AD8Q35873283-EE42DCFD-C386-44FD-A7D1-93BE4857C473Q35889822-C8BF201D-C5A5-4D12-B72D-4AF91DFE569EQ35892542-C87B2445-88B1-486F-88FB-AD6D0B007FE4Q35894752-8A7164E1-C901-4471-A072-5ED0D752A860Q35916166-129BF649-E484-48FE-B23C-3E799015E489Q36035517-B4739BEC-0F2B-4058-B9E9-A46AD878AA5CQ36093736-1DF03C9B-2275-4A75-BCF5-1BC584FF1AB1Q36095153-6205E3BD-C020-4D76-BCAC-638FBEBA7FF5Q36095244-4A1FF04E-B208-4E81-AAD0-CA7785D05432Q36095287-A01EEC8B-7A1B-459C-934C-4E15586E9C43Q36299976-4D4BB49A-FF60-43E2-9D9D-9D0654A7A5BFQ36627147-24735D08-7370-456C-B94D-9598F2231C91Q36814437-C34F87F4-CF1A-4986-9E65-96B25A0BA22BQ36853019-8FE69CCC-D49E-4B7B-B5E3-EA422F0A1098Q36885665-C488EE97-7985-41D1-8F9F-EEFF75809173Q36926042-DEC9C430-838A-4343-A989-9A0AA5C8300FQ37387974-CB9DE448-EABF-4FB5-8DE6-45EB4C37C2ECQ37512764-199BFC72-7218-4ED8-8DEC-A85A133037CCQ38313866-1B0B37F0-C8AE-42B6-8162-F286BF3B0DF7Q38636006-147CC79D-4DE0-4DA1-A661-32807F615D7EQ38711166-0B7EACC7-6A78-4BF9-8EAB-E8C75356B9FAQ38937228-6B6DE5EE-A330-44E9-A89B-E3A7227E2F4AQ39241906-DC4FA851-7762-4DF5-9EE3-840F83FEDF1CQ39698919-E1DEF65F-18F7-4F74-A34D-F4F7E1DDC858Q40202351-5EAA1CB6-5406-44EC-BC09-C542FDA38540Q41684418-3B80CDD7-C864-4FF7-A0BD-E97D9745EFF1Q42361215-8F7CB5A8-8210-483A-B694-0CD78303AE9B
P2860
Impact of chemotherapy dose intensity on cancer patient outcomes.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Impact of chemotherapy dose intensity on cancer patient outcomes.
@ast
Impact of chemotherapy dose intensity on cancer patient outcomes.
@en
Impact of chemotherapy dose intensity on cancer patient outcomes.
@nl
type
label
Impact of chemotherapy dose intensity on cancer patient outcomes.
@ast
Impact of chemotherapy dose intensity on cancer patient outcomes.
@en
Impact of chemotherapy dose intensity on cancer patient outcomes.
@nl
prefLabel
Impact of chemotherapy dose intensity on cancer patient outcomes.
@ast
Impact of chemotherapy dose intensity on cancer patient outcomes.
@en
Impact of chemotherapy dose intensity on cancer patient outcomes.
@nl
P356
P1476
Impact of chemotherapy dose intensity on cancer patient outcomes.
@en
P2093
Gary H Lyman
P304
P356
10.6004/JNCCN.2009.0009
P577
2009-01-01T00:00:00Z